以岭药业(002603.SZ)：撤回“柴黄利胆胶囊”药品注册申请

Core Viewpoint - Yiling Pharmaceutical (002603.SZ) has withdrawn its drug registration application for "Chaihuang Lidan Capsules" as per the notice from the National Medical Products Administration (NMPA) [1] Group 1: Drug Development and Regulatory Updates - The "Chaihuang Lidan Capsules" is an innovative traditional Chinese medicine developed by Yiling, aimed at treating conditions such as chronic cholecystitis and gastrointestinal issues [1] - The NMPA had accepted the new drug registration application for "Chaihuang Lidan Capsules" in June 2024 [1] - Yiling will enhance the registration materials according to the latest NMPA requirements and will resubmit the drug registration application promptly [1] Group 2: Impact on Company Operations - The withdrawal of the registration application is not expected to have a significant impact on the company's current and future operations and performance [1] - The company emphasizes the importance of drug research and development while strictly controlling R&D costs, acknowledging the high risks and long cycles associated with drug development [1] - Yiling will closely monitor the progress of this drug development matter and fulfill its information disclosure obligations as required [1]